# US 2024/0189292 A1 · Substituted pyridine-2,4-dione derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189292 A1
- Document ID: US20240189292A1
- Status: Published application
- Kind: A1
- Application number: 18/278,715
- Filed: 2022-02-25
- Published: 2024-06-13
- Earliest claimed: 2021-02-25
- Assignees: Medshine Discovery Inc.
- Applicants: Medshine Discovery Inc.
- Inventors: Xiaobing YAN; Wei LAI; Charles Z. DING; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20240189292A1

## CPC

- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 221/20: Spiro-condensed ring systems
- C07D 471/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a series of substituted pyridine-2,4-dione derivatives and preparation methods therefor, and in particular, to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A compound of formula (I) or a pharmaceutically acceptable salt thereof,
wherein
R1 and R2 are each independently selected from H, F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, and C1-4 alkoxy, wherein the C1-4 alkyl and C1-4 alkoxy are each independently and optionally substituted by 1, 2, or 3 Ra;
alternatively, R1 and R2 together with the carbon atom to which they are attached form a C3-6 cycloalkyl ring or a 3- to 6-membered heterocycloalkyl ring, wherein the C3-6 cycloalkyl ring and the 3- to 6-membered heterocycloalkyl ring are each independently and optionally substituted by 1, 2, 3, or 4 Rb;
R3 is selected from H and F;
R4 is selected from H, C1-4 alkyl, and C3-4 cycloalkyl, wherein the C1-4 alkyl and C3-4 cycloalkyl are each independently and optionally substituted by 1, 2, or 3 Rc;
R5 is selected from H and C1-4 alkyl;
each R6 is independently selected from H, F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, and C1-4 alkoxy, wherein the C1-4 alkyl and C1-4 alkoxy are each independently and optionally substituted by 1, 2, or 3 Rd;
each Ra is independently selected from F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, C1-4 alkoxy, —CORa1, —CO2Ra1, —SO2Ra1, —SO2NRa1Ra2, and —CONRa1Ra2, wherein the C1-4 alkyl and C1- alkoxy are each independently and optionally substituted by 1, 2, or 3 R;
Ra1 and Ra2 are each independently selected from H and C1-4 alkyl;
alternatively, Ra1 and Ra2 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is independently and optionally substituted by 1, 2, 3, or 4 Re;
each Rb is independently selected from F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, C1-4 alkoxy, —CORb1, —CO2Rb1, —SO2Rb1, —SO2NRb1Rb2, and —CONRb1Rb2, wherein the C1-4 alkyl and the C1-4 alkoxy are each independently and optionally substituted by 1, 2, or 3 R;
Rb1 and Rb2 are each independently selected from H and C1-4 alkyl;
alternatively, Rb1 and Rb2 together with the nitrogen atom to which they are attached form a 4- to 6-membered heterocycloalkyl ring, wherein the 4- to 6-membered heterocycloalkyl ring is independently and optionally substituted by 1, 2, 3, or 4 Rf;
each Rc is independently selected from F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, and C1-4 alkoxy;
each Rd is independently selected from F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, and C1-4 alkoxy;
each Re is independently selected from F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, and C1-4 alkoxy;
each Rf is independently selected from F, Cl, Br, I, —OH, —NH2, —CN, C1-4 alkyl, and C1-4 alkoxy;
each R is independently selected from F, Cl, Br, I, —OH, —NH2, and —CN;
n is selected from 1, 2, 3, or 4;
the 3- to 6-membered heterocycloalkyl ring and the 4- to 6-membered heterocycloalkyl ring each independently comprise 1, 2, 3, or 4 atoms or atomic groups each independently selected from N, O, S, and NH.

### Claim 24 (depends on 23)

The compound or the pharmaceutically acceptable salt thereof according to claim 23, wherein Ra, Rc, Rd, Re, and Rf are each independently selected from F and Cl.

### Claim 25 (depends on 23)

The compound or the pharmaceutically acceptable salt thereof according to claim 23, wherein R1 and R2 are each independently selected from —CH3 and —CH2CH3, wherein the —CH3 and —CH2CH3 are each independently and optionally substituted by 1, 2, or 3 Ra;
or, R3 is selected from H;
or, R4 is selected from —CH3 and —CH2CH3;
or, R5 is selected from H;
or, each R6 is independently selected from H, F, Cl, and —CH3, wherein the —CH3 is optionally substituted by 1, 2, or 3 Rd.

### Claim 26 (depends on 25)

The compound or the pharmaceutically acceptable salt thereof according to claim 25, wherein R1 and R2 are each independently selected from —CH3 and —CH2CH3.

### Claim 27 (depends on 23)

The compound or the pharmaceutically acceptable salt thereof according to claim 23, wherein Rb1 and Rb2 are each independently selected from —CH3 and —CH2CH3.

### Claim 28 (depends on 23)

The compound or the pharmaceutically acceptable salt thereof according to claim 23, wherein each Rb is independently selected from F, Cl, Br, —OCH3, —COCH3, —CO2CH3, and —CO2CH2CH3.

### Claim 29 (depends on 23)

The compound or the pharmaceutically acceptable salt thereof according to claim 23, wherein R1 and R2 together with the carbon atom to which they are attached form or wherein the and are each independently and optionally substituted by 1, 2, 3, or 4 Rb.

### Claim 30 (depends on 29)

The compound or the pharmaceutically acceptable salt thereof according to claim 29, wherein R1 and R2 together with the carbon atom to which they are attached form or .

### Claim 31 (depends on 30)

The compound or the pharmaceutically acceptable salt thereof according to claim 30, wherein R1 and R2 together with the carbon atom to which they are attached form or .

### Claim 32 (depends on 23)

The compound or the pharmaceutically acceptable salt thereof according to claim 23, wherein the structural moiety is selected from and .

### Claim 33 (depends on 25)

The compound or the pharmaceutically acceptable salt thereof according to claim 25, wherein each R6 is independently selected from H, F, Cl, and —CH3.

### Claim 34 (depends on 23)

The compound or the pharmaceutically acceptable salt thereof according to claim 23, wherein the compound has a structure of formula (I-1):

### Claim 35 (depends on 34)

The compound or the pharmaceutically acceptable salt thereof according to claim 34, wherein the compound has a structure of formula (I-1A) or formula (I-1B):
wherein R4 is not H.

### Claim 36

A compound of the following formula or a pharmaceutically acceptable salt thereof, selected from and .

### Claim 37

A compound of the following formula or a pharmaceutically acceptable salt thereof, selected from

### Claim 38 (depends on 23)

A pharmaceutical composition comprising a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof according to claim 23 and a pharmaceutically acceptable carrier.

### Claim 39 (depends on 23)

A method for inhibiting cardiac myosin in a subject in need thereof, comprising:
administering the compound or the pharmaceutically acceptable salt thereof according to claim 23 to the subject.

### Claim 40 (depends on 23)

A method for treating heart failure or hypertrophic cardiomyopathy in a subject in need thereof, comprising: administering the compound or the pharmaceutically acceptable salt thereof according to claim 23 to the subject.

### Claim 41 (depends on 38)

A method for inhibiting cardiac myosin in a subject in need thereof, comprising:
administering the pharmaceutical composition according to claim 38 to the subject.

### Claim 42 (depends on 38)

A method for treating heart failure or hypertrophic cardiomyopathy in a subject in need thereof, comprising: administering the pharmaceutical composition according to claim 38 to the subject.
